Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tetanus toxoid booster study of autoreactive and tetanus-specific B cells in autoimmune disease
NL-OMON58955Phase 4Not yet recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Oct 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of tetanus toxoid in systemic sclerosis (SSc), systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) (4 cohorts), sponsored by Leiden University Medical Center. Primary endpoint: Frequency and phenotype of antigen-specific autoreactive and tetanus toxoid-specific B cells. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
tetanus toxoid
03
Conditions
systemic sclerosis (SSc)systemic lupus erythematosus (SLE)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON58955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58955.